Nurse Practitioner Program year 2025 Reported 2024–2025 Source: CMS Open Payments, 2026 publication

Breanna Yaggy

Nurse Practitioner, Acute Care Branson, MO Nurse Practitioner

NPI 1871328104 CMS profile 11585242

525 Branson Landing Blvd Ste 306, Branson, MO 65616

Open in the dashboard

General payments

$2,929

111 records reported · program years 2024–2025

Research payments

$0

Paid to them · None reported · program years 2024–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Breanna Yaggy of Branson, MO is reported in the CMS Open Payments database as having received $2,929 across 111 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,375 93
2024 General $554 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Breanna Yaggy
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Breanna Yaggy were reported at $2,375. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Breanna Yaggy Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $123 $38–$327 $132
2022 $0 $130 $44–$369 $149
2023 $0 $144 $49–$410 $160
2024 $554 $146 $48–$433 $164
2025 $2,375 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2024–2025
  1. AstraZeneca Pharmaceuticals LP $898 34 payments
  2. Genzyme Corporation $413 14 payments
  3. Regeneron Healthcare Solutions, Inc. $407 13 payments
  4. Inspire Medical Systems, Inc. $183 2 payments
  5. Actelion Pharmaceuticals US, Inc. $164 6 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $106 5 payments
  7. Grifols USA, LLC $95 4 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $91 3 payments
  9. Viatris Specialty LLC $90 5 payments
  10. GlaxoSmithKline, LLC. $89 5 payments
  11. Other $393 20 payments

Every payment, record by record

What the payments were for General payments · program years 2024–2025
  1. Food and Beverage $2,764 109 payments
  2. Education $165 2 payments
Products named General payments · program years 2024–2025
  1. BREZTRI $414 9 payments
  2. DUPIXENT Immunology $413 14 payments
  3. FASENRA $404 11 payments
  4. DUPIXENT Immunology And Inflammation $341 12 payments
  5. AIRSUPRA $247 5 payments
  6. INSPIRE $183 2 payments
  7. OPSUMIT $164 6 payments
  8. UPTRAVI $137 5 payments
  9. TEZSPIRE $119 7 payments
  10. Prolastin-C Liquid $95 4 payments
  11. Other $913 43 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$1,211

Medicare's payments for the services billed

Medicare patients

17

Average age 73

Services billed

19

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 65%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $171
  • Regeneron Healthcare Solutions, Inc. $66
$237 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $45
$45 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $45
$45 — —
GLASSIA
  • Takeda Pharmaceuticals U.S.A., Inc. $35
$35 — —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $33
$33 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

111 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record